RARE – Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.RARE
$16.39Name : Ultragenyx Pharmaceutical Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,670,535,296.00
EPSttm : -5.17
Ultragenyx Pharmaceutical Inc.
$16.39
1.86%$0.31
RARE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
25.33
Margin Of Safety %
Put/Call OI Ratio
0.29
EPS Next Q Diff
0.93
EPS Last/This Y
2.84
EPS This/Next Y
4.11
Price
16.7
Target Price
25.35
Analyst Recom
2.05
Performance Q
-36.69
Upside
-1,187.7%
Beta
0.35
Ticker: RARE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | RARE | 14.92 | 0.30 | 0.26 | 139135 |
| 2026-10-14 | RARE | 14.9 | 0.30 | 0.15 | 139167 |
| 2026-10-15 | RARE | 15.18 | 0.30 | 5.95 | 139270 |
| 2026-10-16 | RARE | 14.55 | 0.30 | 0.73 | 139027 |
| 2026-10-19 | RARE | 15.06 | 0.28 | 0.68 | 94704 |
| 2026-10-20 | RARE | 15.98 | 0.29 | 0.04 | 95181 |
| 2026-10-21 | RARE | 15.91 | 0.28 | 0.22 | 96299 |
| 2026-10-22 | RARE | 15.95 | 0.28 | 0.87 | 96745 |
| 2026-10-23 | RARE | 15.64 | 0.29 | 3.55 | 97396 |
| 2026-10-26 | RARE | 16.04 | 0.29 | 1.01 | 96248 |
| 2026-10-27 | RARE | 16.76 | 0.29 | 0.20 | 96415 |
| 2026-10-28 | RARE | 17.22 | 0.29 | 0.41 | 97367 |
| 2026-10-29 | RARE | 16.78 | 0.29 | 0.13 | 97392 |
| 2026-10-30 | RARE | 16.09 | 0.29 | 0.04 | 97401 |
| 2026-11-02 | RARE | 16.32 | 0.29 | 0.26 | 96950 |
| 2026-11-03 | RARE | 16.63 | 0.29 | 0.66 | 97343 |
| 2026-11-04 | RARE | 17.17 | 0.29 | 0.16 | 97626 |
| 2026-11-05 | RARE | 15.56 | 0.28 | 0.33 | 98066 |
| 2026-11-06 | RARE | 15.42 | 0.29 | 0.44 | 97984 |
| 2026-11-09 | RARE | 16.41 | 0.29 | 1.30 | 95370 |
| 2026-11-10 | RARE | 16.14 | 0.29 | 0.02 | 95409 |
| 2026-11-11 | RARE | 16.7 | 0.29 | 0.43 | 96500 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | RARE | 14.94 | 63.9 | - | -3.87 |
| 2026-10-14 | RARE | 14.91 | 63.9 | - | -3.87 |
| 2026-10-15 | RARE | 15.18 | 63.9 | - | -3.87 |
| 2026-10-16 | RARE | 14.55 | 63.9 | - | -3.93 |
| 2026-10-19 | RARE | 15.07 | 63.9 | - | -3.93 |
| 2026-10-20 | RARE | 15.07 | 63.9 | - | -3.93 |
| 2026-10-21 | RARE | 16.03 | 63.9 | - | -3.93 |
| 2026-10-22 | RARE | 15.96 | 63.9 | - | -3.93 |
| 2026-10-23 | RARE | 15.64 | 63.9 | - | -3.93 |
| 2026-10-26 | RARE | 16.09 | 58.5 | - | -4.08 |
| 2026-10-27 | RARE | 16.76 | 58.5 | - | -4.08 |
| 2026-10-28 | RARE | 17.22 | 58.5 | - | -4.08 |
| 2026-10-29 | RARE | 16.76 | 58.5 | - | -4.08 |
| 2026-10-30 | RARE | 16.09 | 58.5 | - | -4.08 |
| 2026-11-02 | RARE | 16.31 | 58.5 | - | -4.08 |
| 2026-11-03 | RARE | 16.63 | 58.5 | - | -4.08 |
| 2026-11-04 | RARE | 17.16 | 58.5 | - | -4.08 |
| 2026-11-05 | RARE | 15.56 | 58.5 | - | -4.08 |
| 2026-11-06 | RARE | 15.43 | 48.7 | - | -4.08 |
| 2026-11-09 | RARE | 16.41 | 48.7 | - | -4.08 |
| 2026-11-10 | RARE | 16.13 | 48.7 | - | -2.99 |
| 2026-11-11 | RARE | 16.70 | 136.2 | - | -2.99 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | RARE | -0.38 | 1.31 | 22.56 |
| 2026-10-14 | RARE | -0.38 | 1.31 | 22.56 |
| 2026-10-15 | RARE | -0.38 | 1.31 | 22.56 |
| 2026-10-16 | RARE | -0.38 | 1.31 | 22.56 |
| 2026-10-19 | RARE | -0.46 | 1.98 | 22.56 |
| 2026-10-20 | RARE | -0.46 | 1.98 | 22.56 |
| 2026-10-21 | RARE | -0.46 | 1.98 | 22.56 |
| 2026-10-22 | RARE | -0.46 | 1.98 | 22.56 |
| 2026-10-23 | RARE | -0.46 | 1.98 | 22.56 |
| 2026-10-26 | RARE | -0.46 | 4.18 | 22.56 |
| 2026-10-27 | RARE | -0.46 | 4.18 | 22.34 |
| 2026-10-28 | RARE | -0.46 | 4.18 | 22.34 |
| 2026-10-29 | RARE | -0.46 | 4.18 | 22.34 |
| 2026-10-30 | RARE | -0.46 | 4.18 | 22.34 |
| 2026-11-02 | RARE | -0.46 | 3.70 | 22.34 |
| 2026-11-03 | RARE | -0.46 | 3.70 | 22.34 |
| 2026-11-05 | RARE | -0.41 | 3.70 | 22.34 |
| 2026-11-06 | RARE | -0.41 | 3.70 | 22.34 |
| 2026-11-09 | RARE | -0.39 | 1.71 | 21.60 |
| 2026-11-10 | RARE | -0.39 | 1.71 | 21.60 |
| 2026-11-11 | RARE | -0.39 | 1.71 | 25.33 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.16
Avg. EPS Est. Current Quarter
0.47
Avg. EPS Est. Next Quarter
-0.23
Insider Transactions
-0.39
Institutional Transactions
1.71
Beta
0.35
Average Sales Estimate Current Quarter
231
Average Sales Estimate Next Quarter
202
Fair Value
Quality Score
26
Growth Score
47
Sentiment Score
26
Actual DrawDown %
81.1
Max Drawdown 5-Year %
-85.3
Target Price
25.35
P/E
Forward P/E
82
PEG
P/S
2.33
P/B
P/Free Cash Flow
EPS
-5.19
Average EPS Est. Cur. Y
-2.99
EPS Next Y. (Est.)
1.12
Target Price Estimates Raised
3
Target Price Estimates Lowered
5
Profit Margin
-71.78
Relative Volume
0.6
Return on Equity vs Sector %
113
Return on Equity vs Industry %
132.5
EPS 1 7Days Diff
1.1
EPS 1 30Days Diff
0.88
EBIT Estimation
◆
RARE
Healthcare
$16.70
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
53.7
Range 1M
60.4%
Sup Dist
6.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
72.8%
EPS NY
112.9%
52W%
13.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+111% upside
Upside
+111%
Quality
26
RARE — P/E HistoricalBiotechnology
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1371
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
RARE
Latest News
—
Caricamento notizie per RARE…
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading